- Home
- EE vs NEO Comparison
EE vs NEO Comparison
Compare EE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- NEO
- Stock Information
- Founded
- EE 2003
- NEO 2001
- Country
- EE United States
- NEO United States
- Employees
- EE N/A
- NEO N/A
- Industry
- EE Oil/Gas Transmission
- NEO Precision Instruments
- Sector
- EE Utilities
- NEO Health Care
- Exchange
- EE Nasdaq
- NEO Nasdaq
- Market Cap
- EE 941.7M
- NEO 965.2M
- IPO Year
- EE 2022
- NEO 1999
- Fundamental
- Price
- EE $31.59
- NEO $7.42
- Analyst Decision
- EE Hold
- NEO Buy
- Analyst Count
- EE 7
- NEO 9
- Target Price
- EE $32.29
- NEO $13.31
- AVG Volume (30 Days)
- EE 340.7K
- NEO 1.5M
- Earning Date
- EE 05-07-2025
- NEO 07-28-2025
- Dividend Yield
- EE 0.77%
- NEO N/A
- EPS Growth
- EE 37.63
- NEO N/A
- EPS
- EE 1.53
- NEO N/A
- Revenue
- EE $966,414,000.00
- NEO $672,361,000.00
- Revenue This Year
- EE $36.48
- NEO $13.86
- Revenue Next Year
- EE $20.74
- NEO $11.38
- P/E Ratio
- EE $20.27
- NEO N/A
- Revenue Growth
- EE N/A
- NEO 10.10
- 52 Week Low
- EE $16.75
- NEO $6.08
- 52 Week High
- EE $32.99
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- EE 69.11
- NEO 43.69
- Support Level
- EE $28.01
- NEO $7.11
- Resistance Level
- EE $29.53
- NEO $7.72
- Average True Range (ATR)
- EE 0.89
- NEO 0.34
- MACD
- EE 0.20
- NEO 0.03
- Stochastic Oscillator
- EE 97.81
- NEO 33.06
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.